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The world diabetes population quadrupled between 1980 and 2014 to 422 million and the enormous 
impact of Type 2 diabetes is recognised by the recent creation of national Type 2 diabetes prevention 
programmes. There is uncertainty about how to correctly risk stratify people for entry into prevention 
programmes, how combinations of multiple ‘at high risk’ glycemic categories predict outcome, and how 
the large recently defined ‘at risk’ population based on an elevated glycosylated haemoglobin (HbA1c) 
should be managed. We identified all 141,973 people at highest risk of diabetes in our population, and 
screened 10,000 of these with paired fasting plasma glucose and HbA1c for randomisation into a very 
large Type 2 diabetes prevention trial. Baseline discordance rate between highest risk categories was 
45.6%, and 21.3–37.0% of highest risk glycaemic categories regressed to normality between paired 
baseline measurements (median 40 days apart). Accurate risk stratification using both fasting plasma 
glucose and HbA1c data, the use of paired baseline data, and awareness of diagnostic imprecision at 
diagnostic thresholds would avoid substantial overestimation of the true risk of Type 2 diabetes and 
the potential benefits (or otherwise) of intervention, in high risk subjects entering prevention trials and 
programmes.
The world diabetes population quadrupled between 1980 and 2014 to 422 million, with an estimated global prev-
alence in 2014 of 9.0% (95% credible interval 7.2–11.1%) in men and 7.9% (6.4–9.7%) in women1,2. The enormous 
impact of Type 2 diabetes is recognised by the calls for international focus on this issue1,3 and the need for more 
effective diabetes prevention strategies4,5.
The early Type 2 diabetes prevention trials showed a significant impact in reducing the risk of progression 
to Type 2 diabetes over 3 years in intensively managed research populations, largely with impaired glucose tol-
erance (IGT)6,7. Smaller, and more pragmatic studies, then tested the translatability of similar interventions8. 
Meta – analysis of these later studies suggested the probability of metabolic benefit in the short term, though with 
little evidence for immediate impact in Type 2 diabetes prevention, particularly in the less well studied (but very 
prevalent) high risk groups defined by HbA1c criteria8–10. The recent shift from glucose based to HbA1c based 
diagnostic criteria for diabetes has created new substantial populations with non - diabetic hyperglycemia (NDH; 
HbA1c ≥6.0%–<6.5%, ≥42–<48 mmol/mol), identified as at ‘high risk of Type 2 diabetes’, but where clinical 
trial evidence of diabetes prevention benefit from lifestyle intervention is very modest8–11. However, in 2015 
the evidence base was seen as strong enough in the UK to mandate a national diabetes prevention programme 
in England, with entry to the short term intervention programme triggered largely by an NDH HbA1c diag-
nosis (HbA1c ≥6.0%–<6.5%, ≥42–<48 mmol/mol)12,13. Some concerns have been expressed in the UK about 
this ambitious national programme and this approach14,15. There is also a lack of current real world data on 
the prevalence, characteristics, and accessibility of the various at risk glycemic categories in a UK primary care 
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population which makes planning more difficult12,13. The detailed, strongly evidence based, and multiagency USA 
national effort to develop an effective national programme for Type 2 diabetes prevention in the USA has also 
been described very recently16.
Entry to Type 2 diabetes prevention programmes in the UK is now commonly triggered by a single data point 
of an elevated HbA1c ≥6.0%–<6.5%, (≥42–<48 mmol/mol) (NDH). This approach largely ignores the rich lon-
gitudinal epidemiological data describing both HbA1c and fasting plasma glucose as continuous predictor varia-
bles for incident Type 2 diabetes risk, ignores the discordance between these glycemic categories, and ignores the 
substantial added value of combining both HbA1c and fasting plasma glucose in the accurate risk prediction for 
incident Type 2 diabetes17–22. This issue is important, as an estimated 10.7% of the adult population in England 
now have NDH23, and national guidance is that these patients (perhaps 4 million people in England) should now 
have targeted diet and lifestyle advice to reduce the risk of Type 2 diabetes 11. There may be capacity problems in 
delivering this.
To deliver effective intervention and diabetes prevention programmes, we need to understand the hetero-
geneity in the at risk populations entering prevention trials and programmes, and the opportunities for more 
accurate risk classification, risk stratification, in this and similar populations. The aim of this study is to describe 
the baseline characteristics and heterogeneity of the first 10,000 participants at ‘high risk of Type 2 diabetes’ in a 
UK population screened with paired fasting plasma glucose and HbA1c for randomisation into the largest current 
UK diabetes prevention trial.
Participants and Methods
The Norfolk Diabetes Prevention Study (NDPS; www.norfolkdiabetespreventionstudy.nhs.uk) is a 7 year pro-
gramme funded by the UK National Institute of Health Research (NIHR RP-PG–0109–10013) and the full pro-
gramme has been described elsewhere24. NDPS commenced in 2011 and reports in 2018. The programme tests 
the efficacy of an intensive 46 month lifestyle intervention in reducing the risk of transition to Type 2 diabetes for 
people with various ‘prediabetes’ or ‘non - diabetic hyperglycemia’ combinations11,17,18,23. The programme takes 
into account cost and workload pressures, and uses volunteer lay trainers with Type 2 diabetes to support the 
intervention, and randomises subjects with an elevated HbA1c (≥6%–<6.5%; ≥42–<48 mmol/mol) or impaired 
fasting glucose (IFG; fasting plasma glucose ≥5.6–<7.0 mmol/L) or combinations of these categories, but does 
not undertake oral glucose tolerance tests as a primary screening test to detect people with impaired glucose 
tolerance (IGT)11,17,18.
The classification and terminology for people at high risk of Type 2 diabetes based on a glucose or HbA1c that 
are elevated, but not into the diabetes diagnostic range, is complex and includes overlapping categories of predi-
abetes, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), impaired glucose regulation (IGR), or 
non - diabetic hyperglycemia (NDH)11,17. In this paper, we restrict the term non - diabetic hyperglycemia (NDH) 
to participants with HbA1c ≥6%–<6.5% (≥42–<48 mmol/mol) and impaired fasting glucose (IFG) to partici-
pants with fasting plasma glucose of ≥6.1–<7.0 mmol/L or ≥5.6–<7.0 mmol/L depending on the classification 
criteria used11,17,18.
The programme identifies people at high risk of these categories through existing general practice (primary 
care) databases, and screens invited participants with paired baseline fasting plasma glucose and HbA1c to iden-
tify those suitable for randomisation. We contacted 194 general practices in Norfolk, Suffolk and North East 
Essex in England and by 1st March 2016, 135 practices were active collaborators, with a primary care population 
of 1.8 million. The NDPS used the existing NHS primary care electronic health record (EHR) software such as 
SystmOne or EMIS in each practice. All people without known diabetes in these practices were contacted if EHR 
data suggested they (a) were age ≥50 years with BMI ≥ 30 kg/m2 or (b) age ≥50 years and BMI ≥ 25 kg/m2 if 
there was also a recorded first degree family history of Type 2 diabetes, a history of coronary artery disease, or 
gestational diabetes or c) had any previous record of impaired fasting glucose (IFG) or impaired glucose tolerance 
(IGT) or a fasting plasma glucose of ≥6.1–<7.0 mmol/L or (d) any previous record of HbA1c ≥6.0%–<6.5% 
(≥42–<48 mmol/mol) and a fasting glucose ≥5.6–<6.1 mmol/L. The mean prevalence of these categories on 
GP databases were 11% (a and b combined), 1.7% (c), and 2.7% (d) respectively. We contacted 141,973 people, 
inviting them to participate and 12,778 (9%) registered for participation, with the 10,000th consecutive participant 
completed on 1.3.16. After written informed consent, participants underwent venesection for fasting plasma 
glucose and HbA1c, and biometric and clinical data collection. Participants found to have any elevated fasting 
glucose or HbA1c in a randomisable category on initial testing were informed they had an abnormal (elevated) 
result and were invited to return for a repeat fasting plasma glucose and HbA1c measurement under the same 
conditions and at the same site, which was undertaken a median 40 days (interquartile range 27–69 days) later. 
Participants with a normal fasting plasma glucose (<5.6 mmol/l) or HbA1c <42 mmol/mol were not invited to 
return for a repeat sample. Randomisation into trial only occurred if paired baseline tests were concordant for 
glycemic category. In the early years of this programme (2011–2013), before changes to the new diagnostic crite-
ria for diabetes based on HbA1c11,24 and changes in randomisation criteria in this programme, not all participants 
with an NDH level HbA1c, or a fasting plasma glucose ≥5.6–<6.1 mmol/L, had a repeat test as these categories 
(or combinations of categories) were not randomised into trials at the time. Fasting plasma glucose was measured 
by a hexokinase/G-6-PDH method (Architect c8000: Abbott Diagnostics, Maidenhead, UK). HbA1c was meas-
ured using Affinity high performance liquid chromatography (Hb9210: Menarini Diagnostics Ltd., Wokingham, 
UK). Weight, body mass index (BMI), body fat mass, visceral fat, and body fat percentage was measured using 
a Tanita body fat composition analyser (TANITA - Hoogoorddreef, 1101 BE, Amsterdam,The Netherlands. 
Model BC-420 MA). Data are shown as n (%) or mean and one standard deviation (SD). Probability for trend 
across all categories was calculated using linear regression, logistic regression, and Spearman correlation tests for 
continuous, binary and categorical variables respectively suing Stata software (Stata 14.1/SE. StataCorp. 2015. 
Stata Statistical Software,StataCorp LP). All subjects gave written informed consent to research participation 
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after ethical review and approval from the National Research Ethics Service (NRES), Essex 1 Research Ethics 
Committee (10/H0301/55; 13.1.2011). All methods were performed in accordance with NRES permissions and 
after research governance approval form the sponsor organisation (Norfolk and Norwich University Hospital 
NHS Trust). In line with pre specified NDPS analysis plans, we undertook analysis of the first consecutive 10,000 
patients screened.
Results
Clinical characteristics. The baseline characteristics of the first 10,000 screened participants are shown 
stratified by glycemic category (Tables 1 and 2), and by age and body mass index (Table 3).
2,172 (21.7%) participants had non - diabetic hyperglycemia (HbA1c ≥6.0%–<6.5%; ≥42–<48 mmol/mol). 
They were significantly older, and had significantly different anthropometric data, compared to those with a nor-
mal HbA1c <6. 0% (<42 mmol/mol) (Table 1).
967 (9.7%) had impaired fasting glucose (IFG; ≥6.1–<7.0 mmol/L), and 2,651 (26.5%) had the broader defini-
tion of impaired fasting glucose (fasting plasma glucose ≥5.6–<7.0 mmol/L; Table 2). The two IFG subcategories 
(fasting plasma glucose ≥5.6–≤6.0 mmol/L, or ≥6.1–<7.0 mmol/l) did not differ significantly from each other in 
any clinical or anthropometric data (Table 2).
The prevalence of participants with non - diabetic hyperglycemia (NDH; HbA1c ≥6%–<6.5%, ≥42–
<48 mmol/mol) and/or IFG (fasting plasma glucose ≥6.1–<7.0 mmol/L) by age and BMI category is summarised 
(Table 3). This shows a combined population (n = 2,515; 25.2%) potentially eligible for randomisation into NDPS 
intervention trials. The commonest age group to attend for screening was 65–69 years old (n = 2,149; 21.5%), the 
commonest BMI group was 30–35 kg/m2 (n = 3, 813; 38.1%), and 29% of this combined age and BMI defined 
category had either NDH or IFG (Table 3).
HbA1c % (mmol/mol)
<6% (<42)
≥6%–<6.5% 
(≥42–<48) ≥6.5% (≥48) pa p trendb
N (%) 7342 (73.4) 2172 (21.7) 486 (4.9)
Age (years) 61.3 (9.7) 65.2 (9.6) 64.5 (9.9) <0.001 <0.001
Sex, n (%)
   Female 3870 (52.9) 1055 (48.6) 209 (43.0)
   Male 3448 (47.1) 1117 (51.4) 277 (57.0) <0.001 <0.001
Ethnicity
   White British 6871 (93.6) 2059 (94.8) 438 (90.1)
   White other 182 (2.5) 48 (2.2) 19 (3.9)
   Asian 38 (0.5) 22 (1.0) 6 (1.2)
   Other 57 (0.8) 16 (0.7) 9 (1.9)
   Unknown 194 (2.6) 27 (1.2) 14 (2.9) <0.001 0.78
HbA1c (%) 5.6 (0.25) 6.1 (0.14) 7.0 (0.69) <0.001 <0.001
HbA1c (mmol/mol) 37.4 (2.7) 43.7 (1.5) 52.8 (7.5) <0.001 <0.001
Fasting plasma glucose (mmol/L) 5.1 (0.5) 5.7 (0.6) 6.8 (1.5) <0.001 <0.001
Body mass index (BMI; kg/m2) 30.5 (6.9) 31.2 (5.8) 32.6 (6.4) <0.001 <0.001
BMI Categories (n; %)
   Low (<18.5) 12 (0.2) 2 (0.1) 0 (0.0)
   Normal (18.5 − 24.9) 1122 (15.3) 253 (11.7) 48 (9.9)
   Overweight (25–29.9) 2113 (28.8) 685 (31.7) 125 (25.9)
   Obese (30–39.9) 3711 (50.7) 1071 (49.5) 252 (52.2)
   Very obese (≥40) 368 (5.0) 153 (7.1) 58 (12.0) <0.001 <0.001
Percentage body fat (%) 36.4 (9.1) 37.1 (8.7) 38.3 (8.8) <0.001 <0.001
Visceral fat (kg), 13.7 (4.6) 15.2 (4.8) 16.4 (5.4) <0.001 <0.001
Waist circumference (cm) 103.3 (13.6) 106.4 (13.4) 110.9 (14.0) <0.001 <0.001
Body fat mass (kg) 32.5 (11.9) 33.7 (11.9) 36.6 (13.4) <0.001 <0.001
Smoking status, n (%)
   Current smoker 418 (5.8) 170 (8.0) 39 (8.1)
   Ex-smoker 3142 (43.3) 996 (46.8) 219 (45.5)
   Never smoked 3688 (50.9) 962 (45.2) 223 (46.4) <0.001 <0.001
Table 1. Baseline characteristics stratified by HbA1c category for 10,000 participants at high risk of Type 
2 diabetes screened for randomisation into the Norfolk Diabetes Prevention Study. ap-value comparing the 
‘normal’ <6% (<42 mmol/mol) group with the NDH group (HbA1c ≥6%–<6.5%, ≥42–<48 mmol/mol) 
p-values from chi-squared test or Fisher exact test for small numbers. bp-for trend calculated using linear 
regression for continuous variables, logistic regression for binary variables, Spearman correlation test for 
categorical variables. All data shown as n (%) or mean (1 standard deviation).
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Discordance between glycemic categories. The distribution of glycemic categories is shown in 
Table 4. Only 6,057 (60.6%) had an entirely normal combination of HbA1c <6.0% (<42 mmol/mol) and a fast-
ing plasma glucose <5.6 mmol/L. Only 487 (4.9%) of this population had both NDH (HbA1c ≥ 6.0%–<6.5%; 
≥42–<48 mmol/mol) and IFG (fasting plasma glucose ≥6.1–<7.0 mmol/L) on first screening (Table 4).
There was substantial discordance between glycemic categories (Tables 4–6) as 1,274 of the 2,651 partici-
pants (48.1%) with impaired fasting glucose (fasting plasma glucose ≥5.6 to <7.0 mmol/L) had a normal HbA1c 
(<6.0%,; <42 mmol/mol), and 306 of 967 participants (31.6%) with impaired fasting glucose (fasting plasma glu-
cose ≥6.1–<7.0 mmol/L) had a normal HbA1c (<6. 0%; <42 mmol/mol). In addition, 990 of the 2,172 participants 
(45.6%) with NDH (HbA1c ≥ 6.0%–<6.5%, >42–<48 mmol/mol) had a normal fasting glucose (<5.6 mmol/L).
Screen detected Type 2 diabetes. The prevalence of screen detected Type 2 diabetes is shown (Tables 1 and 2).
Reproducibility of glycemic category at repeat confirmatory baseline sampling (Tables 5–8). 
Of these 10,000 participants, 2,483 (24.8%) were eligible for a repeat fasting plasma glucose and HbA1c as a con-
firmatory baseline test prior to randomisation into an intervention trials.
After a median 40 days later (interquartile range 27–69 days) and prior to any programme intervention, 
repeat baseline confirmatory testing showed that 36.1% of 950 participants with IFG (fasting plasma glucose 
≥6.1–<7.0 mmol/L) now recorded a fasting plasma glucose of <6.1 mmol/L (Table 5). In addition, 21.3% of 1,463 
participants with NDH (HbA1c ≥ 6.0%–<6.5%, ≥42–<48 mmol/mol) now recorded a normal HbA1c (<6%, 
<42 mmol/mol) on repeat baseline testing (Table 6).
At the same baseline sampling interval, participants with newly detected Type 2 diabetes at first testing, 39% 
of 251 participants with Type 2 diabetes based on fasting plasma glucose ≥7.0 mmol/L, and 21.1% of 394 par-
ticipants with Type 2 diabetes based on HbA1c 6.5% (≥48 mmol/L) now recorded a non - diabetes range repeat 
measurement (Tables 5 and 6).
Fasting plasma glucose (mmol/L)
<5.6 5.6–6.0 6.1–6.9 ≥7.0 pa p trendb
n (%) 7106 (71.1) 1684 (16.8) 967 (9.7) 243 (2.4)
Age (years) 61.5 (9.8) 64.2 (9.5) 64.7 (9.7) 62.7 (10.1) 0.20 <0.001
Sex (n; %)
Female 3982 (56.2) 686 (40.8) 372 (38.6) 94 (38.7)
Male 3107 (43.8) 994 (59.2) 592 (61.4) 149 (61.3) 0.20 <0.001
Ethnicity
White British 6665 (93.8) 1572 (93.3) 903 (93.4) 228 (93.8)
White other 172 (2.4) 45 (2.7) 28 (2.9) 4 (1.6)
Asian 40 (0.6) 13 (0.8) 11 (1.1) 2 (0.8)
Other 53 (0.7) 15 (0.9) 9 (0.9) 5 (2.1)
Unknown 176 (2.5) 39 (2.3) 16 (1.7) 4 (1.6) 0.67 0.52
HbA1c (%) 5.6 (0.32) 5.9 (0.36) 6.1 (0.41) 7.0 (1.02) <0.00 <0.001
HbA1c (mmol/mol) 38.1 (3.5) 41 (3.9) 43.7 (4.5) 53.5 (11.2) <0.001 <0.001
Fasting glucose (mmol/L) 5 (0.4) 5.8 (0.1) 6.4 (0.2) 8 (1.4) <0.001 <0.001
BMI; (kg/m2) 30.7 (7.0) 30.8 (5.6) 31 (5.8) 32.5 (5.9) 0.35 0.49
BMI Categories n (%)
Low (<18.5) 13 (0.2) 1 (0.1) 0 (0.0) 0 (0.0)
Normal (18.5–24.9) 1058 (14.9) 220 (13.1) 126 (13.1) 19 (7.8)
Overweight (25–29.9) 1951 (27.5) 566 (33.7) 337 (35.0) 69 (28.4)
Obese(30–39.9) 3692 (52.1) 787 (46.8) 428 (44.4) 127 (52.3)
Very obese(≥40) 371 (5.2) 108 (6.4) 72 (7.5) 28 (11.5) 0.65 0.78
Percentage body fat (%) 36.9 (9.1) 35.7 (8.8) 35.8 (9.0) 37.7 (8.8) 0.85 <0.001
Visceral fat (kg) 13.7 (4.6) 15.1 (4.7) 15.5 (4.9) 16.4 (5.5) 0.10 <0.001
Waist circumference (cm) 103.4 (13.7) 105.9 (13.1) 106.8 (14.1) 110.2 (13.7) 0.12 <0.001
Body fat mass (kg) 32.8 (11.9) 32.6 (11.7) 33.2 (12.7) 36.4 (13.3) 0.23 0.50
Smoking status, n (%)
Current smoker 453 (6.5) 93 (5.6) 56 (5.9) 25 (10.4)
Ex-smoker 2993 (42.7) 794 (48.1) 467 (49.3) 103 (42.7)
Never smoked 3571 (50.9) 765 (46.3) 424 (44.8) 113 (46.9) 0.74 <0.001
Table 2. Baseline characteristics stratified by fasting plasma glucose category for 10,000 participants at high 
risk of Type 2 diabetes, screened for randomisation into the Norfolk Diabetes Prevention Study. ap-value 
comparing the ≥5.6–<6.1 mmol/L fasting plasma glucose group with the ≥6.1–6.9 mmol/L group. p -values 
from chi-squared test or Fisher exact test for small numbers. bp-for trend calculated using linear regression for 
continuous variables, logistic regression for binary variables, Spearman correlation test for categorical variables. 
All data shown as n (%) or mean (1 standard deviation).
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A small proportion of participants with NDH (HbA1c ≥ 6%–<6.5%, ≥42–<48 mmol/mol) or IFG (fasting 
plasma glucose ≥6.1–<7.0 mmol/L) at first baseline measurement recorded a diabetes range repeat baseline 
measurement (7.1% and 11.9% respectively; Tables 5 and 6).
The biochemical differences between subgroups who apparently regressed, progressed, or remained in the 
same glycemic category between paired baseline samples are shown (Tables 7 and 8). There were highly signifi-
cant differences in mean HbA1c and fasting plasma glucose at first baseline sampling between these categories, 
with the ‘regression’ groups having significantly lower mean plasma glucose and HbA1c than ‘progression’ group 
(Tables 7 and 8).
HbA1c % (mmol/mol)
<6% ≥6%–<6.5% ≥6.5%
(<42) (≥42–<48) (≥48)
Normal NDH Type 2 diabetes
Fasting plasma 
glucose (mmol/L)
<5.6 Normal 6067 (60.6%) 990 (9.9%) 59 (0.6%)
≥5.6–<6.1 IFG 968 (9.7%) 625 (6.3%) 91 (0.9%)
≥6.1–6.9 IFG 306 (3.1%) 487 (4.9%) 174 (1.74%)
≥7.0 Type 2 diabetes 11 (0.1%) 70 (0.7%) 162 (1.6%)
Table 4. Distribution of glycemic categories (based on initial baseline data) by HbA1c or fasting plasma 
glucose in 10,000 high risk participants screened for randomisation into the Norfolk Diabetes prevention Study 
(NDPS). Please note these data classifications are based on the first of two baseline sample(s) for HbA1c and 
fasting plasma glucose collected in 10,000 participants. For HbA1c categories, non - diabetic hyperglycemia 
(NDH) is defined as HbA1c ≥6.0%–<6.5% (≥42–<48 mmol/mol) and Type 2 diabetes as HbA1c >6.5% 
(≥48 mmol/mol). For fasting plasma glucose categories, impaired fasting glucose (IFG) is defined as fasting 
plasma glucose ≥5.6–<6.1 mmol/L or ≥6.1–<7.0 mmol/l, depending on IFG definitions11,16,23 and Type 2 
diabetes is defined as a fasting plasma glucose ≥7.0 mmol/l. All data are based on first baseline sample in 10,000 
participants.
BMI (kg/m2)
Age band (yrs) <20 20<25 25–<30 30–<35 35–<40 40–<45 45+ Total
39–44
% 40 6.6 11 11 13 32 31 14
n 5 61 79 185 98 34 16 479
45–49
% 0 9.2 18 11 17 14 22 14
n 12 65 125 246 143 58 23 672
50–54
% 0 7.9 17 15 23 34 25 18
n 8 101 251 490 215 77 44 1,186
55–59
% 18 12 19 21 31 38 23 22
n 11 126 348 568 179 80 35 1,347
60–64
% 6.3 17 25 22 27 33 33 24
n 16 197 508 743 244 79 45 1,832
65–69
% 0 24 25 29 29 28 38 27
n 13 245 694 827 272 69 29 2,149
70–74
% 13 31 37 29 43 36 53 34
n 8 177 467 447 119 33 15 1,266
75–79
% 0 33 35 39 39 50 0 37
n 1 117 325 220 66 14 0 743
80+
% 100 38 42 51 57 75 0 45
n 1 72 139 87 23 4 0 326
Total
% 9.3 21 27 24 28 32 30 25
n 75 1,161 2,936 3,813 1,359 448 207 10,000
Table 3. Prevalence (%) and numbers of participants with impaired fasting glucose and/or non–diabetic 
hyperglycemia in a high risk population of 10,000*. *Prevalences (%) are for a combined category of 
participants potentially suitable for randomisation to trial as they had IFG (fasting plasma glucose ≥6.1–
<7.0 mmol/mol) and/or non–diabetic hyperglycemia (NDH; HbA1c ≥6%–<6.5% (≥42 to <48 mmol/mol)). 
Each cell shows overall numbers of participants (n) screened in each age & BMI category (total n = 10,000), 
with prevalence (%) of categories potentially suitable for randomisation into trial for each cell. All data are based 
on the first baseline sample.
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Repeat baseline sample category
Normal
Non diabetic 
hyperglycema Type 2 diabetes Total
Baseline first HbA1c category
Normal (HbA1c 6%, <42 mmol/mol)a 268 (76.4%) 83 (23.6%) 0 (0%) 351
Non diabetic hyperglycemia (NDH)b 312 (21.3%) 1047 (71.6%) 104 (7.1%) 1463
Type 2 diabetesb 1 (0.3%) 82 (20.8% 311 (78.9%) 394
Table 6. Short term (median 40 days) regression and progression in HbA1c based glycemic categories between 
paired baseline data in 2,208 participants with an elevated initial baseline fasting plasma glucose or HbA1c. 
aSome participants with normal HbA1c (<6%, <42 mmol/mol) are included as also had an elevated fasting 
plasma glucose (≥6.1 mmol/L) on same sample. Please note final total sample size is lower than in Tables 1–3 
as repeat sample not always undertaken as outlined in methods. bNDH defined as HbA1c ≥6.0%–6.5 (≥42 to 
<48 mmol/mol) and Type 2 diabetes defined as HbA1c ≥6.5% (≥48 mmol/mol). Median time between paired 
baseline samples was 40 days (interquartile range 27–69 days). Data shown as n and % for each row.
Repeat baseline sample category
Normal IFG1b IFG2b Type 2 diabetes Total
Baseline first fasting plasma glucose category
Normal (<5.6 mmol/L)a 392 (69.6%) 139 (24.7%) 31 (5.5%) 1 (0.2%) 563
Impaired fasting glucose1 (IFG1)b 121 (27.3%) 186 (41.9%) 125 (28.2%) 12 (2.7%) 444
Impaired fasting glucose2 (IFG 2)b 74 (7.8%) 269 (28.3%) 494 (52.0%) 113 (11.9%) 950
Type 2 diabetesb 3 (1.2%) 15 (6.0%) 80 (31.9%) 153 (61.0%) 251
Table 5. Short term (median 40 days) regression and progression in fasting glucose based glycemic categories 
between paired baseline data in 2,208 participants with an elevated initial baseline fasting plasma glucose or 
HbA1c. aSome participants with normal fasting plasma glucose (<5.6 mmol/L) are included, as they had an 
elevated HbA1c (6%, ≥42 mmol/mol) on same baseline sample. Please note final total sample size is lower than 
in Tables 1–3 as repeat sample not undertaken in small number of IFG 2, and a larger population with IFG1 
as outlined in methods. bIFG1 defined as fasting plasma glucose ≥5.6–<6.1 mmol/L, IFG2 defined as fasting 
plasma glucose ≥6.1–<7.0 mmol/L and Type 2 diabetes defined as fasting plasma glucose ≥7.0 mmol/l11,16. 
Median time between paired baseline samples was 40 days (interquartile range 27–69 days). Data shown as n 
and % for each row.
Regressed Unchanged Progressed Overall p
Non diabetic hyperglycemia
n 312 1047 104
Fasting plasma glucose (mmol/L) 5.6 (0.6)*** 5.9 (0.6) 6.1 (0.7)*** 0.0001
HbA1c % (mmol/mol) 42.8 (1.1)*** 43.9 (1.4) 45.4 (1.4)*** 0.0001
HbA1c (%) 6.1 (0.1)*** 6.2 (1.4) 6.3 (1.4)***
Impaired fasting glucose
n 343 494 113
Fasting plasma glucose (mmol/L) 6.3 (0.2)*** 6.4 (0.2) 6.6 (0.2)*** 0.0001
HbA1c % (mmol/mol) 42.0 (3.9)*** 44.2 (4.3) 46.6 (4.4)*** 0.0001
HbA1c (%) 6.10 (0.36)*** 6.2 (4.3) 6.4 (4.4)***
Table 7. Mean fasting plasma glucose and HbA1c in participants with non - diabetic hyperglycemia a 
or impaired fasting glucose where glycemic category changed (progressed or regressed), or remained 
unchanged, on a repeat second baseline sample taken a median 40 days latera. aNon diabetic hyperglycemia 
(NDH) on first sample defined as HbA1c ≥6% (≥42–<48 mmol/mol) and impaired fasting plasma glucose 
as ≥6.1 mmol/L–<7.0 mmol/l. The term regression means the second baseline sample was HbA1c <6% 
(<42 mmol/mol) or fasting plasma glucose <6.1 mmol/L on repeat baseline sample. The term progression 
means the second baseline sample was HbA1c ≥6.5% (≥48 mmol/mol) or fasting plasma glucose ≥7.0 mmol/L. 
Median 40 days (interquartile range 27–69 days) between paired baseline data. Please note total sample size 
(n = 950) for IFG is slightly lower than in Tables 1–3 as repeat sample not undertaken. ***p < 0.001 compared 
to unchanged group. Across group comparisons by one-way ANOVA model, and two-way comparison is based 
on an independent samples test. Data shown as mean (SD).
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Predictability of concordance in baseline results for an initially abnormal (42–47 mmol/mol) HbA1c. 
In the population with NDH, the probability of regression to a normal HbA1c result on repeat baseline testing 
was highly dependent on the initial HbA1c value (Table 9). For those with an initial HbA1c of 42 mmol/mol, 
40.5% (95% CI 35.6–45.6) regressed to a normal baseline result, compared to 1.1% (95% CI 0–6.1) for those with 
an initial HbA1c of 47 mmol/mol. Participants with an NDH HbA1c of 45, 46, or 47 mmol/mol all had a >90% 
chance of having a concordant NDH HbA1c on repeat baseline testing. For those below this value (42, 43, or 
44 mmol/mol), subcategorising by fasting plasma glucose data at baseline gave added value in predicting NDH 
HbA1c concordance. For example, although 40.5% (95% CI 35.6–45.6) of those an initial HbA1c of 42 mmol/
mol regressed to normal on repeat baseline testing, this value was only 17% in those with an additionally elevated 
fasting plasma glucose (6.1–6.9 mmol/l), but 57% in those with an additionally normal fasting plasma glucose 
(4.5–4.9 mmol/l).
Discussion
There are two principal findings relevant to normal clinical practice and clinical prevention programmes in these data.
Firstly, we found that the NDH population (HbA1c ≥ 6.0%–<6.5%; ≥42–<48 mmol/mol), were very heter-
ogenous with a very high rate of discordance between high risk glycemic categories. Nearly half of the high risk 
NDH subjects (now the dominant high risk glycemic category in current clinical practice in many countries), had 
a completely normal fasting plasma glucose (<5.6 mmol/L) and would be at much lower risk of Type 2 diabetes 
than the smaller group with two combined high risk categories. This heterogeneity has been described in cross 
sectional and epidemiological studies, but not in the context of a mass population screening programme for risk 
stratification and entry to a very large diabetes prevention trial.
Secondly, we found that about one - quarter of the population with a biochemical high risk glycemic category 
(NDH or IFG) recorded a normal result on repeat baseline measurement a median 40 days later, making it dif-
ficult to give participants an accurate risk estimate and correct randomisation pathway. This reinforces the need 
for paired baseline concordant data before giving a diagnosis of NDH. For NDH participants with an HbA1c of 
45–47 mmol/mol inclusive, there was a more than 90% likelihood of a repeat baseline result also showing NDH 
range HbA1c and this allows confidence in correct diagnosis and risk categorisation for these subjects. For NDH 
participants with HbA1c of 42–44 mmol/mol, there is a high rate of regression to normal on repeat baseline test-
ing, and subcategorization by fasting plasma glucose data allows more accurate risk stratification and diagnosis. 
Regressed Unchanged Overall p
Type 2 diabetes (based on HbA1c)
n 83 311
Fasting plasma glucose (mmol/L) 6.2 (0.8)*** 7.3 (1.8) 0.0001
HbA1c % (mmol/mol) 48.9 (1.54)*** 54.7 (9.7) 0.0001
HbA1c (%) 6.6 (0.14)*** 7.2 (0.89) 0.0001
Type 2 diabetes (based on fasting plasma glucose)
n 98 153
Fasting plasma glucose (mmol/L) 7.3 (0.5)*** 8.5 (2.0) 0.0001
HbA1c (mmol/mol) 47.1 (6.5)*** 56.7 (13.2) 0.0001
HbA1c (%) 6.5 (0.54) 7.3 (1.1) 0.0001
Table 8. Mean fasting plasma glucose and HbA1c in participants with a diabetes diagnostic range result on first 
baseline sample, who regressed to a non - diabetes diagnostic category, or remained unchanged, on the repeat 
second baseline sample taken a median 40 days latera. aType 2 diabetes on first sample defined as an HbA1c 
≥6.5% (≥48 mmol/mol) and/or fasting plasma glucose ≥7.0 mmol/L, and median time between paired sample 
40 days (interquartile range 27–69 days) later. The term regression in this Table means the second baseline 
sample recorded was in a non - diabetes diagnostic category (HbA1c <6.5%, <48 mmol/mol or fasting plasma 
glucose <7.0 mmol/L). ***p < 0.001 compared to unchanged group. Data shown as mean (SD).
Initial HbA1c (mmol/
mol)
% normal (<42 mmol/mol) on repeat 
(95% CI)
42 40.5 (35.6–45.6)
43 29.4 (24.4–34.9)
44 13.7 (10.0–18.2)
45 6.6 (3.8–10.7)
46 6.1 (2.9–10.9)
47 1.1 (0.0–6.1)
Table 9. Percentage of patients (% and 95% CI) with an initial non- diabetic hyperglycaemia (NDH) range 
HbA1c (42–47 mmol/mol) who then recorded a normal HbA1c (<42 mmol/mol) on a repeat baseline sample a 
median 40 days later, stratified by initial HbA1c. NDH defined as HbA1c ≥6.0%–6.5% (≥42 to <48 mmol/mol) 
and median time between paired baseline samples was 40 days (interquartile range 27–69 days).
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The groups that regressed to normal between baseline testing also had a significantly lower mean HbA1c and fast-
ing plasma glucose, closer to the lower diagnostic threshold, than those that did not regress. These data suggest 
clinicians need to be more aware of the diagnostic imprecision of a single data point close to these thresholds, and 
the need to avoid a lifelong misdiagnosis.
These are novel observations in the context of stratifying for entry into a diabetes prevention trial or clinical 
prevention programme, and have significant implication for clinical practice.These data suggest the majority of 
people with NDH entering clinical prevention programmes are at much lower risk than assumed as they also 
have a normal fasting glucose, or regress to normal within days of testing. These data are relevant to primary 
care clinicians and planners, as an estimated 10.7% of the adult population in England now have NDH23 and UK 
national guidance is that all of these patients (perhaps 4 million people in England) should have targeted diet and 
lifestyle advice to reduce the risk of Type 2 diabetes11. It remains unclear who will deliver this and where clinical 
resources are limited it seem sensible to identify those at genuinely highest risk using paired baseline data and 
both fasting glucose and HbA1c who are most likely to benefit from an intervention. This approach to risk assess-
ment is similar to that used in mild hypertension or dyslipidaemia, with the use of multiple variables and repeat 
measurements to determine intervention and possible benefit. This additional glucose categorisation also appears 
to have cardiovascular risk assessment benefits in this population25. This approach may also have value in capacity 
planning for other national prevention initiatives16.
The diagnostic cut point of HbA1c ≥6.5% (≥48 mmol/mol) for diabetes is supplanting glucose based crite-
ria11,17,18. This policy shift generates a new large high risk population with HbA1c >6%–<6.5% (≥42–<48 mmol/
mol)11,18, categorised as ‘high risk’ for type 2 diabetes and eligible for intensive lifestyle intervention11. There 
is little trial outcome data for diabetes prevention benefit in this large ‘high risk’ population with an isolated 
elevated HbA1c and a normal fasting plasma glucose, and yet this is the largest population entering the NHS 
England national prevention programme, although other national models use a range of glycemic and biometric 
entry points16. Treating this entire population23 as a homogenous group ignores the rich epidemiological data 
describing the added value of further risk stratification using both HbA1c and fasting glucose in predicting Type 
2 diabetes incidence, and the discordance between the various ‘at risk’ categories. The sub categorisation of the 
‘high risk’ NDH population with HbA1c ≥6.0%–<6.5% (≥42 to <48 mmol/mol) by fasting glucose identifies 
subgroups at very different absolute and relative risks of Type 2 diabetes6,7,17. The presence of a normal fasting 
plasma in the ‘high risk’ population with HbA1c ≥6.0%–<6.5% (≥42–<48 mmol/mol) identifies a subgroup at a 
lower annual risk of progression to Type 2 diabetes, at perhaps only 1–2.5%19–22, while the combination of a ‘high 
risk’ HbA1c ≥6%–<6.5% (≥42–<48 mmol/mol) and an elevated fasting plasma glucose identifies a subgroup at 
a much higher relative and absolute risk of incident type 2 diabetes17–22. This suggests a difference in progression 
rates of between perhaps 4.5% over 3 years for those with NDH and a normal fasting plasma glucose, and perhaps 
up to 24% for those with NDH and an elevated fasting plasma glucose17–22. As the absolute and relative risk of 
Type 2 diabetes in NDH can be so much better defined with an additional fasting glucose data, it seems clinically 
sensible to make a more accurate risk estimate by using additional fasting glucose data, and focussing on highest 
risk NDH groups, rather than a blanket application of an intervention dose in all subjects.
We found a high proportion (21.3%) of participants with NDH had a normal HbA1c result (<6%, <42 mmol/
mol) on repeat baseline testing, and 36.1% with IFG (6.1–6.9 mmol/L) had a fasting plasma glucose <6.1 mmol/L 
after a median 40 days, and before any trial intervention. This very rapid short term regression is a relatively novel 
observation in a clinical prevention trial, and raises questions about the using a single glycemic data point for 
entry to prevention programmes, and how to interpret later clinical end points if many participants in fact had 
regressed to normal within weeks of first measurement. This observation may in part reflect self - intervention 
and lifestyle changes triggered by a first abnormal result26, or some regression to the mean. Groups that showed 
very short term regression or progression were characterised by a mean HbA1c or fasting plasma glucose closer 
to relevant diagnostic thresholds, and these changes may also reflect normal assay variance across this thresh-
old. Regression of an abnormal glucose category to normal after very many years follow up (with or without an 
intervention), is well described27–30, but not very short term regression of an abnormal baseline HbA1c or fasting 
plasma glucose data to normal for subjects entering a prevention trial or programme, beforeintervention. This 
means that as well as one half of the NDH patients having a normal fasting glucose about one quarter also return 
to normal after a few days on repeat testing. It is not possible to assume that those who regress to normal are still 
at the same high risk, as persistently abnormal glucose categories have a higher predictive value for Type 2 diabe-
tes than isolated measurements that regress31,32. However, the true risk of Type 2 diabetes or adverse cardiovascu-
lar outcomes experienced by this unusual population with discordant baseline results remains to be seen, and will 
be available with very long term follow up and accurate outcome data planned after the end of the programme in 
2018. These data also show clearly the diagnostic value in the current policy of using paired concordant baseline 
data in diagnosing diabetes as only 78.9% of those with screen detected Type 2 diabetes (≥6.5%, ≥48 mmol/L) 
had a diabetes range HbA1c a median of 40 days later.
Biochemical measurements for diagnosis or monitoring such as HbA1c need to be interpreted with an under-
standing of Uncertainty of Measurement (UoM), which includes the Total Analytical Error (TAE) and Biological 
Variation. Components of TAE are the analytical imprecision and bias of the method, and Sigma-Metrics (SM) 
provides a benchmark on which a process can be characterised and incorporates both imprecision and bias and 
the SM targets for HbA1c have been published33. The methods used in NDPS conform to quality standards and 
methods standardised to the International Federation of Clinical Chemistry and Laboratory Medicine Reference 
measurement procedure, and the analytical imprecision has been shown to be <3% CV and within-individual 
biological variation is relatively small compared to the between-person variation34,35 in people without diabetes. 
Based on UoM, a change of >4 mmol/mol in measured HbA1c reflects a true change in glycemic category and 
a difference of 6.0% to 6.5% (42 to 48 mmol/mol) in a repeat measurement may simply be accounted for by 
UoM. This uncertainty needs to be acknowledged when categorizing participants, and reinforces the value of 
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paired confirmatory data for glycemic categorization particularly for participants with results close to a diagnostic 
threshold. In addition, there are less commonly acknowledged contributions of lifestyle and genetic variance to 
glycation and HbA1c variability (independent of glycemic profiles)36, as are the effects of aging related impair-
ment in insulin release and advanced glycation end products (AGE) on insulin sensitivity37–39.
One strength of this study is that these 10,000 subjects were drawn from a large ‘at risk of Type 2 diabetes’ 
population identified on routine primary care databases, using the simplest of database search terms (age, BMI 
and/or glycaemic data). This approach is easily translatable to most primary care systems, and is similar both to 
approaches used in many case finding prevention trials and to the NHS England national diabetes prevention 
programme. The population studied are also relatively homogenous in terms of age banding and ethnicity, and 
all biochemical and biometric measurements were undertaken in the same laboratory, and by a small number 
of trained observers. Although the 10,000 subjects described in this study are drawn from a larger approached 
sample, it is not possible to comment on any differences between the consented 10,000 and those who did not 
respond to initial contact. This population is a self - selecting sample to some degree therefore, although likely to 
be similar to the sort of participants who would self - select to participate in any clinical prevention programme 
or diet and lifestyle diabetes prevention programme, and has validity in terms of populations entering prevention 
programmes. The data in this paper can not necessarily be translated to other populations with different ethnici-
ties or identified through other screening strategies, although the suggested approach to correct risk stratification 
should be applied to all populations. We are unable to be clearer on the mechanisms behind our novel observation 
of short term regression to normality in NDH after 40 days at baseline, and before any entry into the trial inter-
vention. If this regression was apparent with only a few days between paired baseline measurements this would 
makes it more likely to be related to UoM in assay measurements, rather than participants making changes in 
lifestyle between paired baseline measurements, but the interval between paired results was a median 40 days. 
One further limitation of this study is that we have only paired baseline data for entry to trial, and not at the sev-
eral interval testing time points during 40 month follow up, so we are not aware if this short term regression to 
normality in paired samples is also apparent in HbA1c and glucose data collected at interval (non - end point) 
tests – clearly if this was the case, it would have very major implications for accurate end point determination in 
both prevention trials and programmes.
These current data suggest very many people entering national prevention programmes or trials based solely 
on a single elevated HbA1c are in fact at much lower risk than is assumed. Risk categorization using both fasting 
plasma glucose and HbA1c data, the use of paired baseline data prior to entry into clinical or research pro-
grammes, and awareness of diagnostic imprecision would mitigate some of these difficulties, and avoid over-
estimation of risk and a lifelong misdiagnosis. This policy would also allow a more focussed risk estimation to 
identify those truly at highest risk of Type 2 diabetes, and most likely to benefit from intervention. These data add 
to the literature on the over diagnosis of risk (with associated stigma and increased anxiety) and overstatement 
of potential benefit, particularly in populations withisolated NDH where trial evidence of diabetes prevention 
benefit form lifestyle intervention is modest14,15,39.
References
 1. NCD Risk Factor Collaboration [NCD-RisC]. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based 
studies with 4·4 million participants. Lancet 387, 1513–1530 (2016).
 2. Public Health England. Diabetes prevalence model (APHO) http://www.yhpho.org.uk/resource/view.aspx?RID = 81090 (accessed 
March 12, 2015).
 3. World Health Organisation Global action plan for the prevention and control of non - communicable diseases 2013–2020. http://
apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf?ua=1 (2013).
 4. Comment. Reducing global diabetes burden by implementing solutions and identifying gaps: a Lancet Commission. Lancet 387, 
1494–95. (2016)
 5. Editorial. Beat diabetes: an urgent call for global action. Lancet 387, 1483 (2016).
 6. Schwarz, P. E., Greaves, C. E., Lindstrom, J., Yates, T. & Davies, M. J. Nonpharmacological interventions for the prevention of Type 
2 diabetes. Nat. Rev Endocrinol 8, 363–373 (2012).
 7. Gillies, C. L. et al. Pharmacological and lifestyle interventions to prevent or delay Type 2 diabetes in people with impaired glucose 
tolerance: systematic review and meta – analysis. BMJ 334, 299–304 (2007).
 8. Dunkley, A. J. et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 
2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care 37, 
922–933 (2014).
 9. Mudaliar, U. et al. Cardiometabolic risk factor changes observed in Diabetes Prevention Programs in US Settings: A Systematic 
Review and Metaanalysis. PLOS Medicine 13, 1–17 (2016).
 10. Sattar, N., Logue, J. & Preiss, D. Research digest: weight loss to prevent and treat diabetes. Lancet Diabetes and Endocrinology 4, 817 
(2016).
 11. National Institute for Health and Clinical Excellence. Public health draft guidance. Preventing type 2 diabetes: risk identification and 
interventions for individuals at high risk. National Institute for Health and Clinical Excellence, London; Available from https://www.
nice.org.uk/guidance/ph38 (2012).
 12. Maruthappu, M., Sood, H. & Keogh, B. Radically upgrading diabetes prevention in England. Lancet Diabetes and Endocrinology 3, 
312–313 (2015).
 13. Torjesen, I. NHS England rolls out world’s first national diabetes prevention programme. BMJ 352, i1669 (2016).
 14. Barry, E., Roberts, S., Finer, S., Vijayaraghavan, S. & Greenhalgh, T. Time to question the NHS diabetes prevention programme. BMJ 
351, h4717 (2015).
 15. Barry, E. et al. Efficacy and effectiveness of screen and treat policies in the prevention of type 2 diabetes. BMJ 356, i6538 (2017).
 16. Ely, E. K. et al. National effort to prevent Type 2 diabetes: Participant – level evaluation of CDCs national diabetes prevention 
programme. Diabetes Care 40, 1331–1341 (2017).
 17. Forouhi, N. et al. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes 
Epidemiology Group. Diabetologia 49, 822–827 (2006).
 18. Morris, D. H. et al. Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. 
Diabetologia 56, 1489–1493 (2013).
www.nature.com/scientificreports/
1 0SCIENTIfIC REPoRtS |  (2018) 8:6240  | DOI:10.1038/s41598-018-24662-y
 19. Chamnan, P. et al. Incidence of Type 2 diabetes using proposed HbA1c diagnostic criteria in the European prospective investigation 
of cancer – Norfolk cohort: implications for preventive strategies. Diabetes Care 34, 950–956 (2011).
 20. Lipska, K. J. et al. Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better 
than one? Diabetes Care 36, 3923–3929 (2013).
 21. Heianza Y. et al. HbA1c 5·7–6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to 
diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 378–385 (2011).
 22. Shottker, B., Raum, E. & Rothenbacher, D. Prognostic value of HbA1c and fasting plasma glucose for incident diabetes and 
implications for screening. Eur J Epidemiology 26, 779–787 (2011).
 23. National Cardiovascular Intelligence Network, “NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycemia. 
About Public Health England,” London; www.gov.uk/phe (2015).
 24. Pascale, M. et al. The Norfolk Diabetes Prevention Study [NDPS]: a 46 month multi - centre, randomised, controlled parallel group 
trial of a lifestyle intervention [with or without additional support from lay lifestyle mentors with Type 2 diabetes] to prevent 
transition to Type 2 diabetes in high risk groups with non - diabetic hyperglycemia, or impaired fasting glucose. BMC Public Health. 
17, 31, https://doi.org/10.1186/s12889-016-3929-5 (2017).
 25. Giráldez-García, C. et al. Cardiometabolic Risk Profiles in Patients With Impaired Fasting Glucose and/or Hemoglobin A1c 5.7% to 
6.4%: Evidence for a Gradient According to Diagnostic Criteria: The PREDAPS Study. Medicine (Baltimore). 94, e1935 (2015).
 26. Youngs, W., Gillibrand, W. P. & Phillips, S. The impact of a prediabetes diagnosis on behaviour change: an integrative literature 
review. Practical Diabetes 33, 5–6 (2016).
 27. Sasaki, A., Suzuki, T. & Horiuchi, N. Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year 
follow up study. Diabetologia 22, 154–157 (1982).
 28. Morsiani, M. et al. Pavels dynamic screening for diabetes type 2.: 14 years results in a district of northern Italy. Med Interne 23, 13–17 
(1985).
 29. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention 
Program Research Group. N. Engl. J Med 346, 393–403 (2002).
 30. Forouhi, N. G., Luan, J., Hennings, S. & Wareham, N. J. Incidence of Type 2 diabetes in England and its association with baseline 
impaired fasting glucose: the Ely study 1990–2000. Diabet Med 24, 200–207 (2007).
 31. Inoue, K., Inoue, M., Matsumoto, M. & Akimoto, K. Persistent fasting hyperglycemia is more predictive of type 2 diabetes than 
transient fasting hyperglycemia. Diabetic Med 29, 75–81 (2012).
 32. Li, G. et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 
20-year follow-up study. Lancet. 371, 1783–1789 (2008).
 33. Weykamp, C. et al. IFCC Task Force on Implementation of HbA1c Standardization. Investigation of 2 models to set and evaluate 
quality targets for HbA1c: biological variation and sigma-metrics. Clin Chem. 61, 752–759 (2015).
 34. John, W. G. et al. Multicentre evaluation of the Premier Hb9210 HbA1c analyser. Clin Chem Lab Med. 53, 319–327 (2015).
 35. Lenters-Westra, E., Røraas, T., Schindhelm, R. K., Slingerland, R. J. & Sandberg, S. Biological variation of Hemoglobin A1c: 
consequences for the diagnosis of diabetes mellitus. Clinical Chemistry 60, 1570–1572 (2014).
 36. Jansen, H. et al. Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their 
interactions in the Lifelines Cohort Study. J Intern Med 273, 283–293 (2013).
 37. Santulli, G. et al. Age related impairment in insulin release: the essential role of B(2) adrenergic receptor. Diabetes 61, 692–701 
(2012).
 38. Cassese, A. et al. In skeletal muscle, advanced glycation end products (AGEs) inhibit insulin action and induce the formation of 
multi molecular complexes including the receptor for AGEs. J Biol Chem 283, 36088–99 (2008).
 39. Yudkin J. S. & Montori V. M. The epidemic of pre-diabetes: the medicine and the politics. BMJ 349, g4485. Erratum in: BMJ. 
2014;349: g4683 (2014).
Acknowledgements
We would like to acknowledge the contribution of Aliceon Blair, Andrew Goldson, Sara Auckland, Debbie 
Thompson and Sarah Wilson in delivering this programme. This paper presents independent research funded by 
the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme 
(Reference Number RP – PG − 0109 − 10013). The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health. Additional funding came from the NIHR Clinical 
Research Network (Eastern) and the Norfolk and Norwich University Hospital NHS Trust. The funding source(s) 
had no role in data collection, writing or any version of this manuscript. We are grateful to the NIHR CRN 
for supporting this programme. This paper presents independent research funded by the National Institute for 
Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP 
– PG − 0109−10013). The views expressed are those of the author(s) and not necessarily those of the NHS, the 
NIHR or the Department of Health.
Author Contributions
M.J.S. took the lead in writing this paper, and all revisions, designed the programme, and is C.I. for the NDPS 
programme and guarantor for this paper. T.E.-S. undertook data analysis of completed dataset, and helped draft 
and revise the paper, M.O.B. helped design the original programme and helped draft and revise the paper, A.C. 
drafted the statistical analysis plan for the whole programme, is trial statistician, undertook statistical analysis of 
the full dataset, and helped draft and revise the paper, K.K.D. helped design the original programme and helped 
draft and revise the paper, C.F. helped with data collection, programme infrastructure and accrual, and helped 
draft and revise the paper, A.H. helped design the original programme and helped draft and revise the paper, 
W.G.J. helped design the original programme and helped draft and revise the paper, G.R. helped with programme 
structure and delivery and helped draft and revise the paper, L.S. undertook initial drafts and data analysis of this 
paper, J.T. helped design the original programme and helped draft and revise the paper, M.P. is NDPS programme 
manager and helped deliver the programme, and helped draft and revise the paper.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 1SCIENTIfIC REPoRtS |  (2018) 8:6240  | DOI:10.1038/s41598-018-24662-y
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
